Innovation Pharmaceuticals Inc. (IPIX)
Stock Price:
$0.270 USD
0.045 (19.95%)
Updated Aug 3, 2020 5:19 PM EDT - End of day
Key Info
| Market Cap |
89.14M |
| Revenue (ttm) |
400,000 |
| Net Income (ttm) |
-6.69M |
| Shares Out |
292.75M |
| EPS (ttm) |
-0.03 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 3, 2020 |
| Last Price |
$0.270 |
| Previous Close |
$0.225 |
| Change ($) |
0.045 |
| Change (%) |
19.95% |
| Day's Open |
0.218 |
| Day's Range |
0.215 - 0.297 |
| Day's Volume |
1,035,908 |
| 52-Week Range |
0.050 - 0.650 |
More Stats
| Market Cap |
89.14M |
| Enterprise Value |
90.77M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
292.75M |
| Float |
248.45M |
| EPS (basic) |
-0.03 |
| EPS (diluted) |
-0.03 |
| FCF / Share |
-0.02 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
0.60 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
222.84 |
| PB Ratio |
n/a |
| Revenue |
400,000 |
| Operating Income |
-4.54M |
| Net Income |
-6.69M |
| Free Cash Flow |
-3.67M |
| Net Cash |
-1.63M |
| Net Cash / Share |
0.00 |
| Gross Margin |
n/a |
| Operating Margin |
-1,135.25% |
| Profit Margin |
-1,671.20% |
| FCF Margin |
-918.50% |
| ROA |
-70.82% |
| ROE |
n/a |
| ROIC |
126.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -6.45 | -13.94 | -15.34 | -12.65 | -12.96 | -8.04 | -2.98 | -4.20 | -5.72 | -3.36 |
| Net Income | -8.68 | -16.36 | -15.54 | -12.85 | -13.15 | -8.25 | -3.22 | -4.89 | -5.94 | -3.43 |
| Shares Outstanding | 178 | 145 | 127 | 120 | 115 | 105 | 94.98 | 90.16 | 90.30 | 91.86 |
| Earnings Per Share | -0.05 | -0.11 | -0.12 | -0.11 | -0.11 | -0.10 | -0.04 | -0.06 | -0.06 | -0.04 |
| Operating Cash Flow | -6.33 | -13.28 | -11.71 | -9.89 | -13.07 | -7.51 | -1.91 | -0.69 | -0.74 | -1.11 |
| Capital Expenditures | 0.04 | 0.01 | -0.06 | -0.07 | -0.01 | -0.02 | - | - | - | - |
| Free Cash Flow | -6.29 | -13.27 | -11.77 | -9.96 | -13.08 | -7.53 | -1.91 | -0.69 | -0.74 | -1.11 |
| Cash & Equivalents | 0.58 | 2.42 | 4.14 | 6.31 | 8.41 | 4.99 | 2.96 | 0.03 | 0.07 | 0.00 |
| Total Debt | 1.92 | 2.02 | 2.02 | 2.02 | 2.02 | 2.02 | 2.02 | 2.02 | 2.52 | 1.47 |
| Net Cash / Debt | -1.34 | 0.40 | 2.12 | 4.29 | 6.39 | 2.97 | 0.93 | -1.99 | -2.45 | -1.46 |
| Assets | 4.05 | 6.54 | 9.11 | 11.45 | 14.32 | 10.85 | 2.97 | 0.03 | 0.31 | 0.10 |
| Liabilities | 8.18 | 8.69 | 10.58 | 8.48 | 7.30 | 9.65 | 8.14 | 7.65 | 7.60 | 4.90 |
| Book Value | -4.13 | -2.15 | -1.46 | 2.96 | 7.02 | 1.21 | -5.17 | -7.63 | -7.29 | -4.80 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Innovation Pharmaceuticals Inc. |
| Country |
United States |
| Employees |
4 |
| CEO |
Leo Ehrlich |
Stock Information
| Ticker Symbol |
IPIX |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: IPIX |
Description
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its's lead drug compound is Brilacidin, which is in Phase III study for the treatment of oral mucositis, inflammatory bowel disease, and acute bacterial skin and skin structure infection. The company also develops Kevetrin, a lead anti-cancer compound for treating ovarian cancer. In addition, it owns other compounds for treating diseases, including autism, arthritis, asthma, MS/ALS/Parkinson's, cancer, hypertensive emergency, and bacterial and fungal infections. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Beverly, Massachusetts.